Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 4/20 | 0.35 |
| ▸ | LAP3 | P28838 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594149 | 0.91 | PPARD (0.34) | PPARDEPHX1 | |
| SCHEMBL7204587 | 0.87 | PTPN1 (0.35) | PTPN1PTPN2PPARAEPHX1 | |
| SCHEMBL7592249 | 0.85 | ALDH1A1 (0.35) | PTPN1PTPN2EPHX1 | |
| SCHEMBL7599756 | 0.82 | PTPN1 (0.39) | PTPN1PTPN2LAP3PPARAANPEP | |
| SCHEMBL5393726 | 0.80 | ACP3 (0.36) | PTPN1PTPN2ACP3LAP3PPARA | |
| SCHEMBL7592123 | 0.79 | EPHX1 (0.36) | EPHX1 | |
| SCHEMBL5408355 | 0.78 | PTPN2 (0.35) | PTPN1PTPN2ACP3LAP3PPARA | |
| SCHEMBL7594345 | 0.78 | PTPN1 (0.44) | PTPN1PTPN2ACP3PPARA | |
| SCHEMBL7598595 | 0.78 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL5414183 | 0.78 | TSHR (0.38) | PTPN1PTPN2LAP3PPARAANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | claimed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885PTPN2 24/4885ACP3 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.